학술논문
Phase 2 dose-ranging study to evaluate the efficacy and safety of liposomal irinotecan (LY01610) as a second-line treatment for patients with relapsed small cell lung cancer
Document Type
Article
Author
Source
In eClinicalMedicine September 2024 75
Subject
Language
ISSN
2589-5370